These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 11398153

  • 1. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Aguilar-Salinas CA, Fanghänel-Salmón G, Meza E, Montes J, Gulías-Herrero A, Sánchez L, Monterrubio-Flores EA, González-Valdez H, Gómez Pérez FJ.
    Metabolism; 2001 Jun; 50(6):729-33. PubMed ID: 11398153
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
    Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF, Kontopoulos AG.
    Am J Cardiol; 1997 Sep 01; 80(5):608-13. PubMed ID: 9294990
    [Abstract] [Full Text] [Related]

  • 3. Ciprofibrate versus gemfibrozil in the treatment of primary hyperlipidaemia.
    Knipscheer HC, de Valois JC, van den Ende B, Wouter ten Cate J, Kastelein JJ.
    Atherosclerosis; 1996 Jul 01; 124 Suppl():S75-81. PubMed ID: 8831919
    [Abstract] [Full Text] [Related]

  • 4. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
    Rizos E, Bairaktari E, Ganotakis E, Tsimihodimos V, Mikhailidis DP, Elisaf M.
    J Cardiovasc Pharmacol Ther; 2002 Oct 01; 7(4):219-26. PubMed ID: 12490967
    [Abstract] [Full Text] [Related]

  • 5. Ciprofibrate effects on carbohydrate and lipid metabolism in type 2 diabetes mellitus subjects.
    Hernández-Mijares A, Lluch I, Vizcarra E, Martínez-Triguero ML, Ascaso JF, Carmena R.
    Nutr Metab Cardiovasc Dis; 2000 Feb 01; 10(1):1-6. PubMed ID: 10812581
    [Abstract] [Full Text] [Related]

  • 6. Effects of simvastatin and ciprofibrate alone and in combination on lipid profile, plasma fibrinogen and low density lipoprotein particle structure and distribution in patients with familial combined hyperlipidaemia and coronary artery disease.
    Kontopoulos AG, Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Mayroudi MC, Boudoulas H.
    Coron Artery Dis; 1996 Nov 01; 7(11):843-50. PubMed ID: 8993943
    [Abstract] [Full Text] [Related]

  • 7. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
    Insua A, Massari F, Rodríguez Moncalvo JJ, Rubén Zanchetta J, Insua AM.
    Endocr Pract; 2002 Nov 01; 8(2):96-101. PubMed ID: 11942772
    [Abstract] [Full Text] [Related]

  • 8. Ciprofibrate therapy normalises the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia.
    Bruckert E, Dejager S, Chapman MJ.
    Atherosclerosis; 1993 Apr 01; 100(1):91-102. PubMed ID: 8318067
    [Abstract] [Full Text] [Related]

  • 9. Ciprofibrate increases plasma concentration of platelet-derived growth factor AB in patients with advanced atherosclerosis and hyperlipidemia independently of its hypolipidemic effects.
    Gajdos M, Mongiellová V, Huttová D, Cibulová L, Krivosíková Z, Spustová V, Dzúrik R.
    J Cardiovasc Pharmacol; 2001 Nov 01; 38(5):651-6. PubMed ID: 11602811
    [Abstract] [Full Text] [Related]

  • 10. Ciprofibrate and lipid profile.
    Chandler HA, Batchelor AJ.
    Lancet; 1994 Jul 09; 344(8915):128-9. PubMed ID: 7912363
    [No Abstract] [Full Text] [Related]

  • 11. Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
    Betteridge DJ, O'Bryan-Tear CG.
    Postgrad Med J; 1996 Dec 09; 72(854):739-43. PubMed ID: 9015467
    [Abstract] [Full Text] [Related]

  • 12. Gemfibrozil in hyperlipidaemia: an open, single blind trial.
    Varthakavi PK, Turakhia DP, Sharma SS, Salgaonkar DS, Nihalani KD, Joshi VR.
    J Assoc Physicians India; 1990 Feb 09; 38(2):136-40. PubMed ID: 2380132
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
    Bruckert E, De Gennes JL, Malbecq W, Baigts F.
    Clin Cardiol; 1995 Nov 09; 18(11):621-9. PubMed ID: 8590530
    [Abstract] [Full Text] [Related]

  • 14. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study.
    Mikhailidis DP, Jagroon IA.
    Metabolism; 2001 Nov 09; 50(11):1385-6. PubMed ID: 11715936
    [No Abstract] [Full Text] [Related]

  • 15. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.
    Bermúdez-Pirela V, Souki A, Cano-Ponce C, Bermúdez-Arias F, Mengual-Moreno E, Leal-Gonzalez E, Lemus-Antepaz M, de Bravo MC, de Díaz AA, de Pirela NL, Cano-Peñaloza R, Puche-Medina G, Arraiz N, Reyna-Villazmil N, Contreras F, Israili ZH, Valasco M.
    Am J Ther; 2007 Nov 09; 14(2):213-20. PubMed ID: 17414592
    [Abstract] [Full Text] [Related]

  • 16. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC, Brown LE, Stone PH, Silverman DI, Gibson CM, Sacks FM.
    Ann Intern Med; 1996 Oct 01; 125(7):529-40. PubMed ID: 8815751
    [Abstract] [Full Text] [Related]

  • 17. Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia.
    Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Pehlivanidis AN, Kontopoulos AG.
    J Cardiovasc Risk; 2002 Feb 01; 9(1):33-9. PubMed ID: 11984215
    [Abstract] [Full Text] [Related]

  • 18. The atherogenic role of triglycerides and small, dense low density lipoproteins: impact of ciprofibrate therapy.
    Chapman MJ, Bruckert E.
    Atherosclerosis; 1996 Jul 01; 124 Suppl():S21-8. PubMed ID: 8831912
    [Abstract] [Full Text] [Related]

  • 19. Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels.
    Schaefer EJ, Lamon-Fava S, Cole T, Sprecher DL, Cilla DD, Balagtas CC, Rowan JP, Black DM.
    Atherosclerosis; 1996 Nov 15; 127(1):113-22. PubMed ID: 9006811
    [Abstract] [Full Text] [Related]

  • 20. Cerivastatin in the treatment of mixed hyperlipidemia: the RIGHT study. The Cerivastatin Study Group. Cerivastatin Gemfibrozil Hyperlipidemia Treatment.
    Farnier M.
    Am J Cardiol; 1998 Aug 27; 82(4B):47J-51J. PubMed ID: 9737646
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.